[Effect of Magnesium Sulfate, Nifedipine Tablet Combined Salvia Injection on ET-1/NO, TXA2/PGI2 and Hemorheology of Preeclampsia Patients].
OBJECTIVE
To observe the effect of magnesium sulfate, Nifedipine Tablet (NT) combined Salvia Injection (SI) on endothelin-1 (ET-1), nitric oxide (NO), thromboxane A2(TXA2), prostacyclin I2(PG2), and hemorheology of preeclampsia patients.


METHODS
Totally 704 preeclampsia patients were randomly assigned to the treatment group and the control group, 352 cases in each group. All patients were treated with magnesium sulfate combined NT (on the first day: slow intravenous injection of magnesium sulfate 5 g + intravenous dripping of magnesium sulfate injection 10 g + oral administration of NT 30 mg; on the second and third day, intravenous dripping of magnesium sulfate injection 10 g + oral administration of NT 30 mg), while those in the treatment group were dripped with SI additionally at 20 mL per day for 3 consecutive days. Before and after treatment plasma levels of endothelin-1 (ET-1), nitric oxide (NO), TXA2, PGi2, and hemorheology indicators [such as high blood viscosity (HBV), low blood viscosity (LBV), plasma viscosity (PV), erythrocyte rigidity index (ERI), fibrinogen (FIB)] of two groups were detected.


RESULTS
Compared with the same group before treatment, serum levels of ET-1, TXA2, HBV, LBV, PV, ERI, and FIB decreased in the two groups after treatment (P <0. 05), but levels of NO and PG2 increased (P <0. 05). Compared with the control group in the same period, levels of ET-1, TXA2, HBV, LBV, PV, ERI, and FIB decreased in the treatment group after treatment (P <0. 05), but levels of NO and PGI2 increased (P <0. 05).


CONCLUSIONS
Magnesium sulfate, NT combined SI could effectively regulate the balance of ET-1/NO and TXA2/PGI2, and improve hemorheology of preeclampsia patients.
Xiao-ying
XY
Zheng
Jing
J
Yao
Jia-mei
JM
Zhu
Mei
M
Li
Shu-qiong
SQ
Qiu
Zhao-xia
ZX
Zhu
Ming
M
Zhang
D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D019332:Endothelin-1 / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism; D005260:Female; D018056:Hemorheology; D006801:Humans; D007267:Injections; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D009543:Nifedipine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D009569:Nitric Oxide / Q000378:metabolism; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D027544:Salvia; D013607:Tablets; D013928:Thromboxane A2 / Q000378:metabolism
D004365:Drugs, Chinese Herbal; D019332:Endothelin-1; D013607:Tablets; D009569:Nitric Oxide; D013928:Thromboxane A2; D008278:Magnesium Sulfate; D011464:Epoprostenol; D009543:Nifedipine